NASDAQ:ALVR AlloVir (ALVR) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free ALVR Stock Alerts $0.79 -0.03 (-3.68%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.78▼$0.8250-Day Range$0.72▼$0.8252-Week Range$0.62▼$6.12Volume173,971 shsAverage Volume281,428 shsMarket Capitalization$90.30 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AlloVir alerts: Email Address AlloVir MarketRank™ Stock AnalysisAnalyst RatingReduce1.83 Rating ScoreUpside/Downside2,255.2% Upside$18.50 Price TargetShort InterestBearish5.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.04Based on 6 Articles This WeekInsider TradingSelling Shares$29,132 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.47) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.54 out of 5 starsMedical Sector695th out of 921 stocksBiological Products, Except Diagnostic Industry117th out of 154 stocks 2.9 Analyst's Opinion Consensus RatingAlloVir has received a consensus rating of Reduce. The company's average rating score is 1.83, and is based on 1 buy rating, 3 hold ratings, and 2 sell ratings.Amount of Analyst CoverageAlloVir has received no research coverage in the past 90 days.Read more about AlloVir's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.85% of the outstanding shares of AlloVir have been sold short.Short Interest Ratio / Days to CoverAlloVir has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in AlloVir has recently increased by 5.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlloVir does not currently pay a dividend.Dividend GrowthAlloVir does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALVR. Previous Next 1.1 News and Social Media Coverage News SentimentAlloVir has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for AlloVir this week, compared to 2 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AlloVir insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,132.00 in company stock.Percentage Held by Insiders33.85% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of AlloVir is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AlloVir's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AlloVir are expected to grow in the coming year, from ($0.47) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AlloVir is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AlloVir is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlloVir has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about AlloVir's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About AlloVir Stock (NASDAQ:ALVR)Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.Read More ALVR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALVR Stock News HeadlinesMay 1, 2024 | finance.yahoo.comAlloVir, Inc. (ALVR)March 21, 2024 | stockhouse.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMay 11, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.March 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVRMarch 19, 2024 | stockhouse.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMarch 18, 2024 | investorplace.comALVR Stock Earnings: AlloVir Misses EPS for Q4 2023March 17, 2024 | businesswire.comALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities ...March 17, 2024 | businesswire.comALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVRMay 11, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.March 15, 2024 | stockhouse.com4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the FirmMarch 15, 2024 | prnewswire.comALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMarch 14, 2024 | prnewswire.comClass Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law FirmMarch 14, 2024 | stockhouse.com5-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the FirmMarch 12, 2024 | prnewswire.comALVR IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVRMarch 12, 2024 | prnewswire.comAlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVRMarch 11, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMarch 9, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVirMarch 8, 2024 | markets.businessinsider.comALLOVIR INVESTOR ALERT: Kirby McInerney LLP Alerts AlloVir, Inc. (ALVR) Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitMarch 7, 2024 | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVRMarch 6, 2024 | prnewswire.comLost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyMarch 5, 2024 | prnewswire.comROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVRMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVRFebruary 29, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for AlloVir, Inc. (ALVR) InvestorsFebruary 27, 2024 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the FirmFebruary 27, 2024 | prnewswire.comShareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class Action - ALVRFebruary 25, 2024 | prnewswire.comROSEN, NATIONAL TRIAL LAWYERS, Encourages AlloVir, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALVRFebruary 23, 2024 | prnewswire.comLevi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming DeadlineSee More Headlines Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today5/11/2024Next Earnings (Estimated)5/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALVR CUSIPN/A CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees112Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$20.00 Low Stock Price Target$17.00 Potential Upside/Downside+2,255.2%Consensus RatingReduce Rating Score (0-4)1.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.73% Return on Assets-78.86% Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book0.61Miscellaneous Outstanding Shares114,960,000Free Float76,047,000Market Cap$90.30 million OptionableOptionable Beta0.79 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. David L. Hallal (Age 58)Executive Chairman of the Board Comp: $254.38kDr. Diana M. Brainard M.D. (Age 52)CEO & Director Comp: $978.99kMr. Vikas Sinha C.A. (Age 61)CPA, M.B.A., President, CFO & Director Comp: $536.21kMr. Edward Miller J.D. (Age 59)General Counsel & Secretary Comp: $618.39kMr. Brett R. Hagen (Age 51)Chief Accounting Officer Mr. Dana M. Alexander (Age 48)Senior Vice President of Technical Operations Dr. Ann M. Leen Ph.D. (Age 46)Chief Scientific Officer Mr. Ugo Capolino PerlingieriHead & GM of Europe and Middle East OperationsMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer More ExecutivesKey CompetitorsCEL-SCINYSE:CVMCurisNASDAQ:CRISPassage BioNASDAQ:PASGProtalix BioTherapeuticsNYSE:PLXAthira PharmaNASDAQ:ATHAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 16,151 shares on 5/10/2024Ownership: 2.543%Acadian Asset Management LLCBought 1,387,666 shares on 5/10/2024Ownership: 1.381%Marquette Asset Management LLCBought 178,883 shares on 5/7/2024Ownership: 0.156%Vikas SinhaSold 4,957 sharesTotal: $3,965.60 ($0.80/share)Diana BrainardSold 10,240 sharesTotal: $8,192.00 ($0.80/share)View All Insider TransactionsView All Institutional Transactions ALVR Stock Analysis - Frequently Asked Questions Should I buy or sell AlloVir stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" ALVR shares. View ALVR analyst ratings or view top-rated stocks. What is AlloVir's stock price target for 2024? 6 equities research analysts have issued 12-month price targets for AlloVir's shares. Their ALVR share price targets range from $17.00 to $20.00. On average, they anticipate the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 2,255.2% from the stock's current price. View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts. How have ALVR shares performed in 2024? AlloVir's stock was trading at $0.6798 at the start of the year. Since then, ALVR stock has increased by 15.5% and is now trading at $0.7855. View the best growth stocks for 2024 here. When is AlloVir's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our ALVR earnings forecast. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) issued its quarterly earnings data on Friday, March, 15th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.10. What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL). When did AlloVir IPO? AlloVir (ALVR) raised $252 million in an IPO on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are AlloVir's major shareholders? AlloVir's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.54%), Acadian Asset Management LLC (1.38%), BML Capital Management LLC (0.17%), Marquette Asset Management LLC (0.16%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Gilead Sciences, Inc, Jeffrey S Bornstein, Morana Jovan-Embiricos and Vikas Sinha. View institutional ownership trends. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALVR) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
